Postherpetic Neuralgia
📧 Sign up to get email alerts when something new happens for Postherpetic Neuralgia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-04-09FDA Approved: GRALISE — Supplemental Application (Almatica Pharma LLC)
FDA approved a supplemental application for Gralise (gabapentin) submitted by Almatica Pharma LLC. The approved product is used for postherp…
-
FDA approval · 2013-03-28FDA Approved: GRALISE — Supplemental Application (Almatica Pharma LLC)
FDA approved a supplemental application for GRALISE (gabapentin) from Almatica Pharma LLC.
-
FDA approval · 2013-03-27FDA Approved: GRALISE — Supplemental Application (Almatica Pharma LLC)
The FDA approved a supplemental application for GRALISE (gabapentin) submitted by Almatica Pharma LLC.
-
FDA approval · 2013-03-27FDA Approved: HORIZANT — Supplemental Application (Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals))
FDA approved a supplemental application for HORIZANT (gabapentin enacarbil) submitted by Azurity Pharmaceuticals, Inc. (formerly Arbor Pharm…
-
FDA approval · 2013-03-25FDA Approved: GRALISE — Supplemental Application (Almatica Pharma LLC)
The FDA approved a supplemental application for GRALISE (gabapentin) submitted by Almatica Pharma LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-03-21Clinical Trial Update: Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia
Phase IV trial update for GRALISE (gabapentin) in postherpetic neuralgia; the study completed and results were posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-03-13Clinical Trial Update: Lamictal in the Treatment of Post-Herpetic Neuralgia [Phase 2, Phase 3]
Lamictal (lamotrigine) in postherpetic neuralgia has a terminated Phase 2/3 trial. The update provides the trial status but no results in th…
-
CLINICAL_TRIALS trial_result · 2013-02-15Clinical Trial Update: Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN) [Phase 2]
A Phase 2 dose-tolerability titration study to evaluate the efficacy and safety of Perampanel (E2007) in postherpetic neuralgia has been com…
-
CLINICAL_TRIALS trial_result · 2013-02-08Clinical Trial Update: Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN) [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial update reports completion and results posting for perampanel (E2007) evaluating its use in painful diabetic…
-
FDA label_change · 2013-01-31FDA Approved: GRALISE — Supplemental Application (Almatica Pharma LLC)
FDA approved a supplemental application for GRALISE (gabapentin) submitted by Almatica Pharma LLC, resulting in updated labeling for the pro…
-
FDA approval · 2012-12-26FDA Approved: HORIZANT — Supplemental Application (Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals))
FDA approved a supplemental application for Horizant (gabapentin enacarbil) submitted by Azurity Pharmaceuticals (formerly Arbor Pharmaceuti…
-
CLINICAL_TRIALS other · 2012-12-20Clinical Trial Update: Study of Possible Changes in QST After Application of Capsaicin on Patients With Peripheral Neuropathic Pain
Clinical trial update on whether capsaicin application alters quantitative sensory testing in patients with peripheral neuropathic pain (per…
-
FDA label_change · 2012-12-14FDA Approved: QUTENZA — Supplemental Application (Averitas Pharma Inc)
The FDA approved a supplemental application for QUTENZA (capsaicin) submitted by Averitas Pharma Inc, resulting in a labeling change for the…
-
FDA label_change · 2012-11-30FDA Approved: GRALISE — Supplemental Application (Almatica Pharma LLC)
FDA approved a supplemental application for GRALISE (gabapentin) filed by Almatica Pharma LLC, resulting in changes to the labeling.
-
CLINICAL_TRIALS trial_result · 2012-09-10Clinical Trial Update: Study of NGX-1998 for the Treatment of Postherpetic Neuralgia [Phase 2]
This document reports the completion of a Phase 2 clinical trial evaluating NGX-1998 for postherpetic neuralgia.
-
CLINICAL_TRIALS trial_result · 2012-08-24Clinical Trial Update: Efficacy of Etoricoxib on Peripheral Hyperalgesia [Phase 2]
Phase 2 trial assessing etoricoxib for peripheral hyperalgesia was terminated; the study covered several neuropathic pain conditions.
-
FDA approval · 2012-08-08FDA Approved: GRALISE — Supplemental Application (Almatica Pharma LLC)
FDA approved a supplemental application for GRALISE (gabapentin) submitted by Almatica Pharma LLC.
-
CLINICAL_TRIALS trial_result · 2012-06-08Clinical Trial Update: Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia [Phase 2]
A Phase 2 trial evaluating the analgesic efficacy and safety of T-62 in postherpetic neuralgia has been terminated.
-
CLINICAL_TRIALS withdrawal · 2012-06-07Clinical Trial Update: A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak [Phase 2]
A Phase 2 study evaluating an investigational pain medicine for postherpetic neuralgia has been withdrawn.
-
FDA approval · 2012-05-20FDA Approved: GABAPENTIN — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for Gabapentin from Ascend Laboratories, LLC, under an ANDA, indicating approval related to this gen…
-
FDA approval · 2012-05-01FDA Approved: GABAPENTIN — Original Application (Acella Pharmaceuticals, LLC)
FDA approves Acella Pharmaceuticals' Gabapentin generic (ANDA 076403). The approval allows the generic product to be marketed for the same i…
-
FDA approval · 2012-04-19FDA Approved: GABAPENTIN — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for gabapentin from Amneal Pharmaceuticals LLC, authorizing changes to the product under an exis…
-
FDA approval · 2012-04-11FDA Approved: GABAPENTIN — Supplemental Application (Exelan Pharmaceuticals, Inc.)
The FDA approved a supplemental application for gabapentin submitted by Exelan Pharmaceuticals, Inc. This action confirms an approved supple…
-
FDA approval · 2012-04-11FDA Approved: GABAPENTIN — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for gabapentin submitted by Zydus Pharmaceuticals USA Inc. under ANDA 078926.
-
CLINICAL_TRIALS trial_result · 2012-03-29Clinical Trial Update: Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN) [Phase 2]
A Phase 2 study evaluating lidocaine and tetracaine cream for postherpetic neuralgia has completed.